Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Cash & Current Investments: 2013-2025

Historic Cash & Current Investments for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to $191.7 million.

  • Coherus Oncology's Cash & Current Investments rose 96.20% to $191.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $637.7 million, marking a year-over-year increase of 0.51%. This contributed to the annual value of $126.0 million for FY2024, which is 7.00% up from last year.
  • Coherus Oncology's Cash & Current Investments amounted to $191.7 million in Q3 2025, which was down 19.35% from $237.6 million recorded in Q2 2025.
  • Coherus Oncology's Cash & Current Investments' 5-year high stood at $468.7 million during Q3 2021, with a 5-year trough of $82.4 million in Q1 2025.
  • In the last 3 years, Coherus Oncology's Cash & Current Investments had a median value of $131.1 million in 2023 and averaged $152.4 million.
  • As far as peak fluctuations go, Coherus Oncology's Cash & Current Investments skyrocketed by 106.73% in 2021, and later crashed by 68.28% in 2025.
  • Coherus Oncology's Cash & Current Investments (Quarterly) stood at $417.2 million in 2021, then crashed by 54.05% to $191.7 million in 2022, then tumbled by 38.57% to $117.7 million in 2023, then grew by 7.00% to $126.0 million in 2024, then spiked by 96.20% to $191.7 million in 2025.
  • Its Cash & Current Investments stands at $191.7 million for Q3 2025, versus $237.6 million for Q2 2025 and $82.4 million for Q1 2025.